Menthol

證據等級: L5

預測適應症: 0 個

Menthol: Repurposing Evaluation Inconclusive — Insufficient Evidence Pack Data

One-Sentence Summary

Menthol is a naturally occurring cyclic terpene alcohol found in mint plants, widely used in over-the-counter topical and inhalation products. The current Evidence Pack contains no TxGNN-predicted new indications, and the Canadian regulatory lookup returned zero DINs. Without a valid prediction target or baseline safety profile, this candidate cannot be evaluated at this time.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack
Predicted New Indication	None generated
TxGNN Prediction Score	Not available
Evidence Level	Below L5 — no predictions generated
Canada Market Status	Not marketed (0 DINs on record)
Number of DINs	0
Recommended Decision	Hold

Why No Prediction Was Generated

Two probable causes explain the empty predicted_indications list:

1. DrugBank ID not resolved. The Evidence Pack records drugbank_id: null. The TxGNN knowledge graph indexes compounds by DrugBank ID; without a confirmed mapping, the pipeline cannot locate the node for Menthol and therefore produces no candidate diseases. Menthol’s DrugBank entry is DB14783 — this ID must be injected before re-running the prediction step.

2. Zero Health Canada DINs returned. The regulatory lookup found no licensed products with Menthol as the sole active ingredient. Menthol in Canada is most commonly a secondary ingredient in combination OTC products (topical analgesics, throat lozenges, inhalants), which may not be captured by single-ingredient DIN queries. A combination-product search against the Health Canada Drug Product Database is needed.

Because neither a prediction score nor an original approved indication is available, the standard evidence evaluation framework cannot be applied.

Canada Market Information

No DINs are currently on record for Menthol as a standalone active ingredient.

A targeted search of the Health Canada Drug Product Database using ingredient-level filtering (rather than product-level) is recommended. As a reference, Menthol appears as an active or medicinal ingredient in at least 200+ combination products (e.g., muscle rubs, cough syrups, lozenges).

Safety Considerations

No TFDA package-insert warnings, contraindications, or drug interaction data are present in this Evidence Pack. Before any clinical or market assessment can proceed, the following must be retrieved:

Health Canada Product Monograph (if a standalone DIN exists) or representative combination product monographs
DrugBank safety profile for DB14783 (known issues include mucosal irritation, contraindication in infants under 2 years for nasal applications)

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is missing the three minimum data points required to generate a repurposing evaluation: a confirmed DrugBank ID, at least one TxGNN predicted indication, and a baseline safety profile. No assessment of mechanistic plausibility, clinical evidence, or benefit-risk can be made without these inputs.

To proceed, the following is needed:

Resolve DrugBank mapping — Confirm DrugBank ID as DB14783 and re-run the KG prediction pipeline to populate predicted_indications
Fix DIN lookup — Re-query Health Canada DPD using ingredient-level search to recover combination-product DINs and associated approved indications
Retrieve MOA data — Pull mechanism of action from DrugBank API (/v1/drugs/DB14783) to enable mechanistic plausibility analysis
Retrieve safety data — Download and parse at least one representative Health Canada product monograph to populate key_warnings and contraindications
Re-run evidence collection — Once a target indication is available from TxGNN, trigger ClinicalTrials.gov and PubMed collectors to populate the evidence tables
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.